Novel Anticancer Drug Leads

Abstract (Set) A novel target for cancer therapy has been discovered by JHU scientists. The drug azalanstat appears to act as an inhibitor and may be used to develop lead compounds for novel angiogenesis inhibitors. In a series of experiments, where azalanstat and small hairpin RNAs were used to knockdown the novel target, it was found that the target enzyme is required for endothelial cell proliferation. These results indicate that the enzyme is a viable target for azalanstat and other small molecule inhibitors. Description (Set) Proposed Use (Set) This discovery may lead to the development of novel anti-angiogenic agents for the treatment of cancer, diabetic retinopathy, macular degeneration as well as other angiogenesis-dependent diseases.

Inventor(s): Liu, Jun ,Bhat, Shridhar,Xu, Jing

Type of Offer: Licensing



« More Medical Patents

---